PURE Bioscience, Inc. income statement PURE

Annual Quarterly

In fiscal 2026, which ended Jul 31, 2026, PURE Bioscience, Inc. reported revenue of $2.3 million, up 5.3% from the year before. It recorded a net loss of $2.5 million. The operating loss came to $2.1 million, an operating margin of -89.9%. Diluted earnings per share were -$0.02. Across the 9 fiscal years shown, revenue grew from $1.8 million in fiscal 2018 to $2.3 million in fiscal 2026, about 3.4% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Jul 31, 2026	FY 2025 Jul 31, 2025	FY 2024 Jul 31, 2024	FY 2023 Jul 31, 2023	FY 2022 Jul 31, 2022	FY 2021 Jul 31, 2021	FY 2020 Jul 31, 2020	FY 2019 Jul 31, 2019	FY 2018 Jul 31, 2018	FY 2017 Jul 31, 2017
Revenue	2 +5.3%	2 +12.2%	2 +4.6%	2 +1.3%	2 -52.8%	4 -43.2%	7 +262.3%	2 +7.6%	2	—
Cost of revenue	1 +10.3%	1 +10.9%	1 -10.5%	1 +6.2%	1 -53.9%	2 -36.0%	3 +297.8%	1 -4.6%	1 +0.4%	1 +72.3%
Gross profit	1 +1.8%	1 +13.1%	1 +18.6%	1 -2.9%	1 -51.8%	2 -48.4%	4 +240.5%	1 +16.8%	1	—
Research and development	0 +5.1%	0 +4.6%	0 +1.7%	0 -6.9%	0 -5.9%	0 +5.3%	0 -9.0%	0 -22.9%	0 -41.1%	1 -16.0%
Selling, general and administrative	3 -5.6%	3 -18.1%	4 -7.5%	4 +6.2%	4 +0.1%	4 +9.5%	4 -42.4%	6 +22.6%	5 +0.1%	5 +3.0%
Operating expenses	3 -4.6%	4	—	—	—	4 +9.2%	4 -40.7%	7	—	—
Operating income	-2 +8.3%	-2 +28.8%	-3 +19.1%	-4 -5.9%	-4 -61.1%	-2 -57875.0%	0 +100.1%	-6 +20.6%	-7 -17.2%	-6 +14.9%
Income tax	0	0	0	0 -100.0%	0 +0.0%	0 +0.0%	0 +0.0%	0 +0.0%	0 +0.0%	0 +3.1%
Net income	-2 -3.5%	-2 +28.4%	-3 +15.4%	-4 -13.5%	-3 -50.5%	-2 -58075.0%	0 +100.1%	-7 +11.9%	-7 -18.8%	-6 +56.4%
Basic EPS	-0.02 +0.0%	-0.02 +33.3%	-0.03 +25.0%	-0.04 +0.0%	-0.04 -33.3%	-0.03	0.00	—	—	—
Diluted EPS	-0.02 +0.0%	-0.02 +33.3%	-0.03 +25.0%	-0.04	—	-0.03	0.00	—	—	—
Weighted average shares, basic	116 +4.1%	112 +0.0%	112 +0.4%	111	—	87 +6.0%	82	—	—	—
Weighted average shares, diluted	116 +4.1%	112 +0.0%	112 +0.4%	111	—	87 +3.0%	85	—	—	—
Other measures
Depreciation and amortization	0 +50.0%	0 -98.6%	0 +26.5%	0 -45.1%	0 +23.8%	0 -10.4%	0 -20.3%	0 -15.4%	0 +3.3%	0 +26.0%
EBITDA	-2 +8.4%	-2 +25.4%	-3 +20.5%	-4 -9.0%	-4 -64.1%	-2 -1191.3%	0 +103.7%	-5 +20.9%	-7 -17.9%	-6 +16.2%
Interest coverage	-5.12x	-7.60x	-20.59x	—	—	—	—	—	—	—
Margins
Gross margin	57.20%	59.17%	58.69%	51.73%	53.97%	52.84%	58.13%	61.86%	56.99%	—
Operating margin	-89.86%	-103.18%	-162.56%	-210.07%	-200.97%	-58.85%	0.06%	-292.77%	-396.96%	—
Profit margin	-107.12%	-108.95%	-170.66%	-211.03%	-188.40%	-59.05%	0.06%	-343.32%	-419.50%	—
EBITDA margin	-89.73%	-103.09%	-155.02%	-203.84%	-189.48%	-54.47%	2.83%	-280.15%	-380.89%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Miscellaneous Chemical Products (SIC 2890)
Listed as: PURE (OTC)
Fiscal year ends: July 31
Incorporated in: DE
Headquarters: El Cajon, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1006028
Former names: PURE BIOSCIENCE (until Mar 17, 2011); INNOVATIVE MEDICAL SERVICES (until Sep 2, 2003)

Other Miscellaneous Chemical Products companies

Element Solutions Inc ESI
Cabot Corp CBT
WD 40 Co WDFC
Flotek Industries INC/CN/ FTK
Orion S.A. OEC
ASP Isotopes Inc. ASPI
Arq, Inc. ARQ
Flexible Solutions International Inc FSI

All 11 Miscellaneous Chemical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.